HomeClinics HomeAbout ClinicsAll ClinicsHot TopicsAdvancesSpecial OffersCME
Logo
Search for

Volume 15, Issue 1, Pages 109-133 (January 2006)


View previous. 9 of 18 View next.

The Schizophrenia Prodrome: A Developmentally Informed Review and Update for Psychopharmacologic Treatment

Lynelle E. Thomas, MDabCorresponding Author Informationemail address, Scott W. Woods, MDac

In recent years substantial strides have been made in recognizing the prodrome for schizophrenia as a prospective entity in adolescents and young adults. Preliminary data suggest that atypical antipsychotic medications may improve symptoms and delay or prevent progression to schizophrenia, but substantial additional research is needed before the balance of long-term risks and benefits can be confidently assessed. Other medications or psychotherapies might benefit these patients as well. Some centers are beginning to examine if and how currently used prodromal diagnostic strategies and intervention studies might inform recognition and treatment of younger patients possibly prodromal for childhood-onset schizophrenia.

a PRIME Research Clinic, New Haven, CT, USA

b Child Study Center, Yale University School of Medicine, 230 South Frontage Road, New Haven, CT 06520, USA

c Yale University School of Medicine, New Haven, CT, USA

Corresponding Author InformationCorresponding author. Child Study Center, Yale University School of Medicine, 230 South Frontage Road, New Haven, CT 06520

 Dr. Woods has received research grant support from Bristol-Myers Squibb, Eli Lilly, Glytech Inc., and Janssen Research Foundation.

PII: S1056-4993(05)00076-3

doi:10.1016/j.chc.2005.08.011


View previous. 9 of 18 View next.